[Alpha Biz= Reporter Kim Minyoung] The French investment firm Archimed Group is set to initiate a public tender offer worth 724.4 billion won for the KOSDAQ-listed South Korean aesthetic medical device company Jeisys Medical.
Archimed plans to invest up to 1 trillion won, including the cost of acquiring management control shares and the public tender offer, to secure nearly 100% ownership of Jeisys Medical. Following the acquisition, the company is expected to proceed with delisting Jeisys Medical from the stock exchange.
According to the investment banking (IB) industry on the 10th, Archimed Group, through its subsidiary Syracuse Subco Ltd., intends to carry out a public tender offer for 55,724,838 common shares of Jeisys Medical, representing a 72% stake.
The planned tender offer price is approximately 13,000 won per share, which is 20.81% higher than the previous trading day's closing price of 10,760 won. The tender offer will be conducted over 43 days, from June 10 to July 22. NH Investment & Securities will be responsible for managing the tender offer.
Alphabiz Kim Minyoung (kimmy@alphabiz.co.kr)
